AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences, Inc. (OTCQB: ACUT) announced that Chairman Gabriele Cerrone has purchased 20,000 shares of ACUT, increasing his total holdings to 3,821,226 shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AccuStem Sciences, Inc. (OTCQB: ACUT) announced that Chairman Gabriele Cerrone has purchased 20,000 shares of ACUT, increasing his total holdings to 3,821,226 shares. This purchase reflects Cerrone's confidence in the company's trajectory and potential in the life sciences sector focused on cancer treatment. AccuStem is dedicated to improving cancer patient outcomes through innovative solutions and comprehensive care approaches.
Positive
- Chairman Gabriele Cerrone's purchase of 20,000 shares indicates strong insider confidence.
- Total shares held by Cerrone now stands at 3,821,226, reflecting a significant investment in the company.
Negative
- None.
Details
News Market Reaction – ACUT
The recorded move for ACUT in the trading session of this news was -16.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and PHOENIX, Ariz., June 09, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased 20,000 ACUT shares in the open market. This brings his total holdings to 3,821,226 shares.
About AccuStem
AccuStem is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology - to empower patients and their care team with critical answers and tools and drive innovation in healthcare.
Media Contact:
Jeff Fensterer
Phone: 415-640-6010
Email: jeff@accustem.com
Investor Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.